Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2005 2
2006 1
2009 1
2010 1
2012 2
2013 1
2014 2
2016 3
2017 1
2018 3
2019 1
2020 2
2021 10
2022 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Neutralization of SARS-CoV-2 Variants by rVSV-ΔG-Spike-Elicited Human Sera.
Yahalom-Ronen Y, Erez N, Fisher M, Tamir H, Politi B, Achdout H, Melamed S, Glinert I, Weiss S, Cohen-Gihon I, Israeli O, Izak M, Mandelboim M, Caraco Y, Madar-Balakirski N, Mechaly A, Shinar E, Zichel R, Cohen D, Beth-Din A, Zvi A, Marcus H, Israely T, Paran N. Yahalom-Ronen Y, et al. Among authors: mechaly a. Vaccines (Basel). 2022 Feb 14;10(2):291. doi: 10.3390/vaccines10020291. Vaccines (Basel). 2022. PMID: 35214749 Free PMC article.
Neutralizing Monoclonal Anti-SARS-CoV-2 Antibodies Isolated from Immunized Rabbits Define Novel Vulnerable Spike-Protein Epitope.
Makdasi E, Levy Y, Alcalay R, Noy-Porat T, Zahavy E, Mechaly A, Epstein E, Peretz E, Cohen H, Bar-On L, Chitlaru T, Cohen O, Glinert I, Achdout H, Israely T, Rosenfeld R, Mazor O. Makdasi E, et al. Among authors: mechaly a. Viruses. 2021 Mar 26;13(4):566. doi: 10.3390/v13040566. Viruses. 2021. PMID: 33810465 Free PMC article.
The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants.
Makdasi E, Zvi A, Alcalay R, Noy-Porat T, Peretz E, Mechaly A, Levy Y, Epstein E, Chitlaru T, Tennenhouse A, Aftalion M, Gur D, Paran N, Tamir H, Zimhony O, Weiss S, Mandelboim M, Mendelson E, Zuckerman N, Nemet I, Kliker L, Yitzhaki S, Shapira SC, Israely T, Fleishman SJ, Mazor O, Rosenfeld R. Makdasi E, et al. Among authors: mechaly a. Cell Rep. 2021 Sep 7;36(10):109679. doi: 10.1016/j.celrep.2021.109679. Epub 2021 Aug 21. Cell Rep. 2021. PMID: 34464610 Free PMC article.
rVSV-ΔG-SARS-CoV-2-S vaccine: repeated intramuscular (IM) toxicity, local tolerance, immunogenicity and biodistribution study in NZW rabbits.
Rosner A, Steiner M, Melamed S, Politi B, Vitner E, Tamir H, Achdout H, Cherry L, Avraham R, Yahalom-Ronen Y, Levy H, Beth-Din A, Stein D, Mechaly A, Fisher M, Fatelevich E, Weiss S, Kronfeld N, Madar-Shapiro L, Nyska A, Yitzhaki S, Paran N, Israely T, Marcus H, Madar-Balakirski N. Rosner A, et al. Among authors: mechaly a. Arch Toxicol. 2022 Aug;96(8):2329-2339. doi: 10.1007/s00204-022-03302-5. Epub 2022 May 17. Arch Toxicol. 2022. PMID: 35577986 Free PMC article.
Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice.
Noy-Porat T, Mechaly A, Levy Y, Makdasi E, Alcalay R, Gur D, Aftalion M, Falach R, Leviatan Ben-Arye S, Lazar S, Zauberman A, Epstein E, Chitlaru T, Weiss S, Achdout H, Edgeworth JD, Kikkeri R, Yu H, Chen X, Yitzhaki S, Shapira SC, Padler-Karavani V, Mazor O, Rosenfeld R. Noy-Porat T, et al. Among authors: mechaly a. iScience. 2021 May 21;24(5):102479. doi: 10.1016/j.isci.2021.102479. Epub 2021 Apr 26. iScience. 2021. PMID: 33937725 Free PMC article.
36 results